January 2nd 2018: Encore: Research Update From Summit Therapeutics on Ridinilazole |eCard

SIGN-UP NOW! Click to become a The VoiceAmerica Talk Member for Free!

C. diff. Spores and More

Tuesday at 10 AM Pacific

January 2nd 2018: Encore: Research Update From Summit Therapeutics on Ridinilazole

Join Us With Guest Dr. Richard Vickers, Ph.D., Chief Scientific Officer at Summit Therapeutics joining us to discuss their research on a new antibiotic to treat a C. difficile infection. Learn more about Ridinilazole, clinical trials and the progress being made and moving closer to getting an urgently needed new treatment available for CDI to patients.

DOWNLOAD PDF

GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel

LISTEN LIVE

EPISODE ON DEMAND

VIEW HOST PAGE

Questions? Comments?
Call In Live! Call-In
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guest

Richard Vickers Ph.D.

Dr. Vickers is Chief Scientific Officer, Antimicrobials and Programme Lead for CDI, Summit Therapeutics. He joined Summit in 2003 and during his time has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs.

Read more

Share This Episode

Share On Facebook

Share On Twitter

Share On LinkedIn

Share this E-mail

https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 29/04/2024 08:00 29/04/2024 09:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join Us With Guest Dr. Richard Vickers, Ph.D., Chief Scientific Officer at Summit Therapeutics joining us to discuss their research on a new antibiotic to treat a C. difficile infection. Learn more about Ridinilazole, clinical trials and the progress being made and moving closer to getting an urgently needed new treatment available for CDI to patients. VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY

Add to Calendar

Email the Host

Connect with VoiceAmerica

Download our mobile apps